T. Rowe Price Investment Management Inc. Invests $78.75 Million in Metsera Inc. $MTSR

Key Points

• T. Rowe Price Investment Management Inc. has invested approximately $78.75 million in Metsera Inc., acquiring 2,893,009 shares, which represents 2.75% ownership as of their most recent SEC filing.
• Several other institutional investors also established positions in Metsera, including Alphabet Inc. with an investment of $135 million, and Jennison Associates LLC with $9.67 million.
• Metsera's stock has a consensus rating of "Buy" from five analysts, with a target price ranging around $55.00 to $65.00.

T. Rowe Price Investment Management Inc. acquired a new position in Metsera Inc. (NASDAQ:MTSR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,893,009 shares of the company's stock, valued at approximately $78,748,000. T. Rowe Price Investment Management Inc. owned 2.75% of Metsera at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. New York State Common Retirement Fund bought a new position in shares of Metsera during the first quarter valued at about $131,000. Invesco Ltd. bought a new stake in shares of Metsera in the 1st quarter worth approximately $271,000. Deutsche Bank AG purchased a new stake in shares of Metsera in the first quarter worth $374,000. Nuveen LLC purchased a new stake in Metsera during the 1st quarter valued at about $553,000. Finally, Bank of New York Mellon Corp purchased a new position in Metsera in the 1st quarter worth approximately $884,000.

Analyst Ratings Changes

A number of brokerages recently weighed in on MTSR. Bank of America increased their price objective on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday. Wells Fargo & Company assumed coverage on Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective on the stock. Finally, Guggenheim boosted their price objective on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Metsera has a consensus rating of "Buy" and an average price target of $59.00.

Metsera Stock Performance

Shares of MTSR traded up $1.00 during trading hours on Thursday, hitting $36.02. The stock had a trading volume of 743,258 shares, compared to its average volume of 1,002,154. The firm has a 50-day moving average price of $33.73 and a 200 day moving average price of $28.44. Metsera Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.